Skip to main content

Perrigo Company Value Stock - Dividend - Research Selection

Perrigo

ISIN: IE00BGH1M568 , WKN: A1XAEY

Market price date:
Market price:  


Fundamental data and company key figures of the share

Annual reports in
Key figures
Cash flow
Net operating cash flow
Capital Expenditures
Free cash flow
Balance sheet
Total Equity
Liabilities & Shareholders equity
Income statement
Net income
Eps (diluted)
Diluted shares outstanding
Net sales/revenue

Fundamental ratios calculated on:

Ratios
Key figures
Cash flow
P/C
 
P/FC
Balance sheet
ROI
ROE
Income statement
P/E
Div. Yield %
P/B
P/S


Do you want to do make a detailed fundamental analysis of this stock?

✓ NEW Fundamental API Access to 500 data points per month
Fundamental data up to 25 years
Comparison to all other stocks by the FScore
Time saving!

How our site works ...

Non-binding 7 days without automatic subscription
 No termination required after the free week
Finanzoo fundamental analysis
Data updated daily
Virtual depots
Share alarms via email
Subscription can be canceled at any time at the end of the month 
Choice of desired shares
Over 2000 stock analyzes available
Bitcoin payment possible if you do not want to subscribe

Price for monthly subscription $ 19.99 / month including VAT.



Description Data
Symbol
Market Capitalization USD
Country
Indices
Sectors
Raw Data Source
Stock Split
Internet


Description of the company

Perrigo Company plc, a healthcare company, manufactures and supplies over-the-counter (OTC) healthcare products, infant formulas, branded OTC products, and generic pharmaceutical products worldwide. The company operates through Consumer Healthcare Americas, Consumer Healthcare International, and Prescription Pharmaceuticals segments. It offers OTC products in cough, cold, allergy, sinus, analgesic, gastrointestinal, smoking cessation, infant formula and food, animal health, diagnostic, lifestyle, personal care and derma-therapeutics, natural health and vitamins, and anti-parasite categories. The company also develops, manufactures, and markets a portfolio of generic prescription drugs, such as creams, ointments, lotions, gels, shampoos, foams, suppositories, sprays, liquids, suspensions, solutions, powders, controlled substances, injectables, hormones, oral solid dosage forms, and oral liquid formulations. In addition, it offers contract manufacturing services. The company offers its products through retail drug, supermarket, and mass merchandise chains; hospitals; pharmacies; wholesalers; drug and grocery stores; and para pharmacies, as well as through a network of pharmacy sales force in North America, Europe, Australia, Israel, and China. Perrigo Company plc was founded in 1887 and is headquartered in Dublin, Ireland.

The Finanzoo GmbH assumes no liability for the accuracy of the information! All information is provided without warranty. Sources:: www.bundesanzeiger.de, www.sec.gov,


NEWS


Canaccord Genuity Maintains Buy on Perrigo, Lowers Price Target to $17

2026-02-27
Canaccord Genuity analyst Susan Anderson maintains Perrigo (NYSE:PRGO) with a Buy and lowers the price target from $20 to $17.

Perrigo Company plc (NYSE:PRGO) Stock Falls 6.7% After Q4 Earnings and Revenue Miss Estimates

2026-02-26
Perrigo shares drop after Q4 earnings and revenue miss Wall Street estimates, despite reported market share gains.

Perrigo Company plc 2025 Q4 - Results - Earnings Call Presentation

2026-02-26
2026-02-26. The following slide deck was published by Perrigo Company plc in conjunction with their 2025 Q4 earnings call.

Perrigo Company plc (PRGO) Q4 2025 Earnings Call Transcript

2026-02-26

12 Health Care Stocks Moving In Thursday's Pre-Market Session

2026-02-26

Perrigo Sees FY2026 Adj EPS $2.25-$2.55 vs $2.65 Est; Sees Sales $4.019B-$4.189B vs $4.171B Est

2026-02-26
Perrigo (NYSE:PRGO) is looking for FY2026 Adj EPS of $2.25-$2.55 vs $2.65 analyst estimate. sees sales of $4.019 billion-$4.189 billion vs $4.171 billion analyst estimate.

Perrigo Sees FY2026 Adj EPS $2.25-$2.55 vs $2.65 Est,

2026-02-26
Perrigo (NYSE:PRGO) is looking for FY2026 Adj EPS of $2.25-$2.55 vs $2.65 analyst estimate..

Perrigo Q4 Earnings Summary & Key Takeaways

2026-02-26

Perrigo Q4 Adj. EPS $0.77 Misses $0.79 Estimate, Sales $1.138B Beat $1.102B Estimate

2026-02-26
Perrigo (NYSE:PRGO) reported quarterly earnings of $0.77 per share which missed the analyst consensus estimate of $0.79 by 3.02 percent. This is a 17.2 percent decrease over earnings of $0.93 per share from the same

Earnings Scheduled For February 26, 2026

2026-02-26